Crucell N.V. is acquiring Xcellerex, Inc.’s FlexFactory bioproduction line and multiple XDR single-use bioreactors as part of its effort to expand capacity and flexibility of its manufacturing capabilities. The project will deliver new, validated clinical manufacturing capacity at Crucell’s operations in Leiden, The Netherlands during 1Q10. Financial terms were not disclosed. “The FlexFactory purchase is an important part of our product development strategy as we build capacity to suppo...